CDH 1
Alternative Names: CDH1Latest Information Update: 31 Oct 2021
Price :
$50 *
At a glance
- Originator University of Pennsylvania
- Developer Novapeutics
- Class Small molecules
- Mechanism of Action Menin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA (PO)